Descripción de la empresa
Guardant Health, Inc. operates within the healthcare sector as a precision oncology entity, providing blood and tissue tests alongside comprehensive data sets for diagnostic and research purposes both domestically and internationally. The company's core offerings include the Guardant360 CDx test, designed for tumor mutation profiling via liquid biopsy, and the Guardant360 Liquid test, which analyzes over 740 genes to support clinical applications. In terms of scale, the organization employs approximately 2,490 individuals and holds a market capitalization of $11.10B, with annual revenue reaching $982.02M over the trailing twelve-month period. These valuation and revenue figures indicate that the company maintains a substantial market presence despite operating in a capital-intensive diagnostic industry, suggesting a significant investment in infrastructure and research capabilities. The disparity between its high market cap and negative earnings metrics further contextualizes its position as a growth-oriented biotechnology firm that prioritizes revenue expansion and market penetration over immediate profitability.
Salud financiera
The company reported revenue of $982.02M, a net income of -$416,276,992, and an EBITDA of -$396,561,984 for the trailing twelve months, highlighting a substantial gap between top-line generation and bottom-line profitability. This significant divergence between revenue and net income reveals a cost structure characterized by heavy operational expenditures, likely driven by research and development costs, clinical trial expenses, and sales and marketing outlays typical of the diagnostics industry. Free cash flow stands at -$88,105,872, indicating that the company is currently burning cash, which limits immediate financial flexibility for share buybacks or aggressive debt reduction without external capital infusion. Despite the cash burn, the balance sheet shows a cash position of $1.20B against total debt of $1.71B, resulting in a negative net cash position that requires careful monitoring of liquidity runway. The debt-to-equity ratio is not available, but the current ratio of 4.84 suggests strong short-term liquidity, as the company holds nearly five times more current assets than current liabilities, providing a robust buffer against immediate obligations. Return on Equity is not available due to the negative equity position, while Return on Assets stands at -15.6%, indicating that the asset base is currently generating negative returns relative to the capital deployed. These return metrics reflect the early-stage nature of the business model where asset accumulation and revenue scaling take precedence over generating positive returns on invested capital.
Evaluación de valoración
The trailing twelve-month P/E ratio is not available, whereas the forward P/E ratio is reported at -136.43, a metric that implies the market expects earnings to remain negative or improve slowly in the future. The price-to-book ratio is listed at -111.33, a negative figure that indicates the market is pricing the company's equity at a significant discount relative to its book value, often seen in unprofitable biotech firms. Price-to-sales is valued at 11.30, and the EV/EBITDA stands at -29.27, suggesting that valuation multiples are being derived primarily from revenue quality and market expectations rather than earnings power. The stock trades between a 52-week high of $120.74 and a 52-week low of $36.36, with the current price sitting at a level that reflects high volatility and sensitivity to clinical trial outcomes or regulatory approvals. The beta of 1.69 indicates that the stock price exhibits significantly higher volatility than the broader market, moving roughly 1.69 times as much as the overall market index in response to similar price movements. These valuation metrics collectively suggest a high-risk, high-reward asset profile where traditional valuation anchors like earnings power are absent, forcing reliance on revenue growth and pipeline potential.
Growth & Income
Revenue growth year-over-year stands at 39.4%, demonstrating robust top-line expansion, while earnings growth is not available due to the company's current unprofitable status. Because the earnings growth rate is not applicable, the disparity between strong revenue expansion and negative earnings implies that the company is reinvesting heavily into operations to drive future profitability rather than distributing profits. As a non-dividend payer, the company does not offer a dividend yield or has a payout ratio of 0.0%, confirming that all available cash is retained within the business to fund research, development, and commercialization efforts. This reinvestment strategy aligns with the typical lifecycle of a precision oncology company that must sustain high R&D burn rates to secure long-term market share. The overall growth and income profile characterizes Guardant Health as a pure-play growth investment that offers no current income but delivers rapid revenue acceleration in a specialized healthcare niche.